Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Sclar

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
The American Journal of Medicine|January 4, 2014
Anaphylaxis: a payor's perspective on epinephrine autoinjectorsJeffrey D Dunn, David A Sclar
BMJ (Clinical Research Ed.)|December 1, 2018
Need for international classification of gabapentin as a controlled substanceAlyssa M Peckham, David A Sclar
Journal of Dietary Supplements|March 23, 2012
Factors associated with the use of St. John's wort among adults with depressive symptomsChung-Hsuen Wu, Jae Kennedy, David A Sclar
Expert Opinion on Drug Safety|October 7, 2017
Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?Alyssa M Peckham, Kathleen A Fairman, David A Sclar
Clinical Therapeutics|August 25, 2009
Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent PsychiatryTracy L Skaer, David A Sclar, Linda M Robison
The Primary Care Companion for CNS Disorders|June 1, 2013
Selegiline transdermal system: use pattern and adherence in patients with major depressive disorderDavid A Sclar, Lawrence J Cohen, Kimberly Blanchard Portland
Therapeutics and Clinical Risk Management|August 24, 2017
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practiceKathleen A Fairman, Lindsay E Davis, David A Sclar
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Psychiatric Services (Washington, D.C.)|December 13, 2005
Datapoints: trends in ADHD and stimulant use among adults: 1995-2002Linda M Robison, David A Sclar, Tracy L Skaer
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
The American Journal of Medicine|January 4, 2014
Anaphylaxis: a payor's perspective on epinephrine autoinjectorsJeffrey D Dunn, David A Sclar
BMJ (Clinical Research Ed.)|December 1, 2018
Need for international classification of gabapentin as a controlled substanceAlyssa M Peckham, David A Sclar
Journal of Dietary Supplements|March 23, 2012
Factors associated with the use of St. John's wort among adults with depressive symptomsChung-Hsuen Wu, Jae Kennedy, David A Sclar
Expert Opinion on Drug Safety|October 7, 2017
Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?Alyssa M Peckham, Kathleen A Fairman, David A Sclar
Clinical Therapeutics|August 25, 2009
Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent PsychiatryTracy L Skaer, David A Sclar, Linda M Robison
The Primary Care Companion for CNS Disorders|June 1, 2013
Selegiline transdermal system: use pattern and adherence in patients with major depressive disorderDavid A Sclar, Lawrence J Cohen, Kimberly Blanchard Portland
Therapeutics and Clinical Risk Management|August 24, 2017
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practiceKathleen A Fairman, Lindsay E Davis, David A Sclar
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Psychiatric Services (Washington, D.C.)|December 13, 2005
Datapoints: trends in ADHD and stimulant use among adults: 1995-2002Linda M Robison, David A Sclar, Tracy L Skaer
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Pageof 6